Heather Manos
Addiction Medicine · Charlotte, NCNPI 1427186022
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations.
Across 108 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$331
- Viiv Healthcare Company$179
- Braeburn Inc.$159
- AbbVie$154
- Alkermes, Inc.$149
- Amgen$145
- plus $1K from 34 others
What the payments were for
- Food & beverage$2,47499%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 15 | $331 |
| Viiv Healthcare Company | 7 | $179 |
| Braeburn Inc. | 3 | $159 |
| AbbVie | 8 | $154 |
| Alkermes, Inc. | 6 | $149 |
| Amgen | 2 | $145 |
| Gilead | 6 | $121 |
| MDD US Operations, LLC | 1 | $119 |
| USWM, LLC | 6 | $107 |
| Napo Pharmaceuticals Inc | 5 | $90 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $67 |
| Novo Nordisk | 4 | $67 |
| E.r. Squibb & Sons, L.L.C. | 3 | $67 |
| Novartis | 2 | $62 |
| Antares Pharma, Inc. | 3 | $60 |
| AstraZeneca | 3 | $56 |
| Abbott | 2 | $54 |
| Pfizer | 3 | $54 |
| Johnson & Johnson | 3 | $53 |
| Merck | 2 | $33 |
| Insightec,inc | 1 | $33 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Seqirus USA Inc | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Theratechnologies Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Edwards Lifesciences | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Tolmar, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Orexo US, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Intuity Medical Inc | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| VBI Vaccine (delaware) Inc. | 1 | $14 |
| Forte Bio-pharma LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,501 in reported general payments places this provider in the 80th percentile of 42 addiction medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 111 | $16,819 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 13 | $5,818 |
| Varenicline Tartrate | 13 | $3,703 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 17 | $1,239 |
| Naltrexone Hcl | 14 | $1,203 |
| Duloxetine Hcl | 12 | $286 |
| Quetiapine Fumarate | 19 | $275 |
| Olanzapine | 12 | $244 |
| Gabapentin | 17 | $240 |
| Prazosin Hcl | 11 | $115 |
| Buspirone Hcl | 22 | $83 |
| Clonazepam | 17 | $44 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 14 | $41 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Orexo US, Inc.Zubsolv | $16 | $5,81813 claims |
| Lilly USA, LLCOlanzapine | $15 | $24412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 42 addiction medicine providers in North Carolina.
Other addiction medicine in Charlotte
- Gail GriffinCharlotte$655
- Jonathan ButlerCharlotte$620
- Logan AdamsCharlotte$394
- Afrayem MorganCharlotte$380
- Kelsie PierreCharlotte$324
- Kent SeitzCharlotte$314
- Geeta McGaheyCharlotte$192
- Seif AtyiaCharlotte$143
- Stephanie NewbyCharlotte$95
- Bernard GottschalkWilmington$188K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.